The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase

被引:46
作者
Arion, D
Borkow, G
Gu, ZG
Wainberg, MA
Parniak, MA
机构
[1] SMBD JGH,LADY DAVIS INST MED RES,MONTREAL,PQ H3T 1E2,CANADA
[2] MCGILL UNIV,AIDS CTR,SIR MORTIMER B DAVIS JEWISH GEN HOSP,MONTREAL,PQ H3T 1E2,CANADA
关键词
D O I
10.1074/jbc.271.33.19860
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The K65R mutation in HIV-1 reverse transcriptase (RT) is associated with viral cross-resistance to 2',3'-dideoxyinosine, 2',3'-dideoxycytidine, and 2',3'-dideoxy-3'-thiacytidine. We have found that in vitro DNA synthesis by K65R RT is significantly more processive than that of wild type (wt) RT. Depending on the template/ primer (T/P) used, the total incorporation of nucleotides under single processive cycle conditions was 20-50% higher with K65R RT than with wt RT. With heteropolymeric T/P, the total incorporation of dNMP by K65R and wt RT was similar under continuous DNA synthesis reaction conditions. However, under single processive cycle conditions, the rate of full-length polymerization product synthesis by K65R RT was about S-fold higher than that by wt RT. We also found a decreased rate of T/P dissociation during K65R RT DNA synthesis, which is consistent with the increased processivity of the enzyme. We postulate that the increased processivity of the R65R RT may be a compensatory response to the decreased affinity of this mutant for certain dNTP substrates, allowing normal viral replication kinetics.
引用
收藏
页码:19860 / 19864
页数:5
相关论文
共 25 条
  • [1] ABBOTTS J, 1993, J BIOL CHEM, V268, P10312
  • [2] ARTS EJ, 1994, J BIOL CHEM, V269, P14672
  • [3] SENSITIVITY OF WILD-TYPE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE TO DIDEOXYNUCLEOTIDES DEPENDS ON TEMPLATE LENGTH - THE SENSITIVITY OF DRUG-RESISTANT MUTANTS DOES NOT
    BOYER, PL
    TANTILLO, C
    JACOBOMOLINA, A
    NANNI, RG
    DING, JP
    ARNOLD, E
    HUGHES, SH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (11) : 4882 - 4886
  • [4] ANALYSIS OF MUTATIONS AT POSITION-184 IN REVERSE-TRANSCRIPTASE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    BOYER, PL
    HUGHES, SH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) : 1624 - 1628
  • [5] Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication
    Caliendo, AM
    Savara, A
    An, D
    DeVore, K
    Kaplan, JC
    DAquila, RT
    [J]. JOURNAL OF VIROLOGY, 1996, 70 (04) : 2146 - 2153
  • [6] IDENTIFICATION OF THE NUCLEOTIDE-BINDING SITE OF HIV-1 REVERSE-TRANSCRIPTASE USING DTTP AS A PHOTOAFFINITY LABEL
    CHENG, N
    MERRILL, BM
    PAINTER, GR
    FRICK, LW
    FURMAN, PA
    [J]. BIOCHEMISTRY, 1993, 32 (30) : 7630 - 7634
  • [7] HIV RESISTANCE TO REVERSE-TRANSCRIPTASE INHIBITORS
    DECLERCQ, E
    [J]. BIOCHEMICAL PHARMACOLOGY, 1994, 47 (02) : 155 - 169
  • [8] PARAMETERS THAT INFLUENCE PROCESSIVE SYNTHESIS AND SITE-SPECIFIC TERMINATION BY HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE ON RNA AND DNA TEMPLATES
    DESTEFANO, JJ
    BUISER, RG
    MALLABER, LM
    FAY, PJ
    BAMBARA, RA
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1131 (03) : 270 - 280
  • [9] ASSOCIATION OF REVERSE-TRANSCRIPTASE WITH POLYNUCLEOTIDE TEMPLATES DURING CATALYSIS
    DUBE, DK
    LOEB, LA
    [J]. BIOCHEMISTRY, 1976, 15 (16) : 3605 - 3611
  • [10] Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase
    Fletcher, RS
    Holleschak, G
    Nagy, E
    Arion, D
    Borkow, G
    Gu, ZX
    Wainberg, MA
    Parniak, MA
    [J]. PROTEIN EXPRESSION AND PURIFICATION, 1996, 7 (01) : 27 - 32